MERZ-AESTHETICS
20.10.2020 12:38:06 CEST | Business Wire | Press release
Merz Aesthetics, a global leader in medical aesthetics, today announced that Radiesse® is celebrating ten million syringes shipped worldwide over almost twenty years. Radiesse® is a unique calcium hydroxylapatite (CaHA) injectable filler1 used for volumization, lifting and contouring, as well as skin rejuvenation by stimulating natural collagenogenesis.2,3 The product portfolio includes Radiesse® and Radiesse® Lidocaine delivering effective and natural-looking cosmetic results, distinguished by its established safety profile4 and high patient satisfaction.5
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201020005619/en/
“As we reflect on this milestone, we are proud of the fact that, Radiesse has proven to provide aesthetic practitioners with a unique treatment that they can administer confidently, while supporting their patients’ desired impact,” said Kristel Hectors, Head of Marketing EMEA, Merz Aesthetics. “With almost twenty years of scientific evidence and clinical experience, Radiesse is such a unique product and full of opportunities and possibilities. As we are looking ahead, we are excited for what’s to come over the next years for Radiesse.”
The milestone campaign launching under the tagline “The Power Used By Millions” reinforces the uniqueness of the product and its working mechanism. Informing health care professionals and educating patients on the uniqueness of Radiesse® , on its working mechanism and efficacy.
“Radiesse is my number one go to product because of its versatility. Radiesse plus for contouring, lifting, ligaments and volumizing. Classic Radiesse for classic indications like folds and of course hyperdiluted Radiesse for skin quality improvement,” said Jani van Loghem, MD Cosmetisch arts KNMG. “It is a biostimulatory product going beyond a hyaluronic acid: the collagen will be giving the patient the final result and it is a really nice message to the patient! That’s why I choose Radiesse.”
About Radiesse®
/Radiesse®
(+) Lidocaine
Radiesse®
is an injectable dermal filler that provides immediate volume and correction and continues to work by stimulating the body’s own natural collagen production. In addition, Radiesse activated the self-renewing potential within the skin to make the skin firm, elastic and strong. Radiesse can be tailored to individual requirements and skin condition.1,6-10
Radiesse® (+) Lidocaine injectable implant is an opaque, dermal filler that contains a small quantity of local anesthetic (lidocaine). In Europe, Radiesse® (+) Lidocaine is indicated for plastic / reconstructive procedures, including deep dermal and subdermal soft tissue augmentation of the facial area and for restoration and correction of facial volume loss. The presence of lidocaine is intended to reduce patient pain and to enhance comfort during treatment.1,6-10
Radiesse® / Radiesse® (+) Lidocaine is valued by doctors and patients around the world for its tolerability and safety profile. Radiesse received the CE mark for aesthetic use in Europe in 2004, with U.S. FDA approval following in 2006. In that time, Radiesse has been considered a leading minimally-invasive aesthetic treatment trusted by healthcare providers around the world. The product has been available on the market for more than fifteen years, with now 10 million syringes shipped worldwide and a clinically proven safety profile supported by more than 200 clinical studies and peer-reviewed publications.1,6-10
Radiesse is available in more than 70 countries worldwide.
About Merz Aesthetics
At Merz Aesthetics, we are a medical aesthetics business with a long history of empowering health care professionals, patients and employees to live every day with confidence. We aim to help people around the world look, feel and live like the best versions of themselves. Clinically proven, our product portfolio includes injectables, devices and skin care treatments designed to meet each patient’s needs with the highest standards of safety and efficacy. We are known for building unique connections with customers who feel like family. Our global headquarters is in Raleigh, N.C., USA, with locations in 32 countries worldwide. Merz Aesthetics is part of Merz Group, a family owned company founded in 1908 and based in Frankfurt, Germany. Learn more at merzaesthetics.com.
Copyright © 2020 Merz Pharmaceuticals GmbH. All rights reserved. MERZ, MERZ AESTHETICS and the MERZ logo are registered trademarks of Merz Pharma GmbH & Co. KGaA. Radiesse® is a registered trademark of Merz North America, Inc.
1 RADIESSE Instructions for Use Nov. 2017. RADIESSE® Lidocaine Instructions for Use Jun.2018.
2 Berlin AL, et al. Dermatol Surg. 2008;34(suppl 1):S64-S67.
3 Moers-Carpi M, et al. Dermatol Surg. 2007;33(suppl 2):S144-S151.
4 Van Loghem JV, et al. J Clin Aesthet Dermatol. 2015:8(1)38-49.
5 Juhász MLW, Marmur ES, Dermatol Surg. 2018;44(8)1084-93.
6 Yutskovskaya Y, et al. J Drugs Dermatol. 2014;13(9):1047-52.
7 Yutskovskaya YA, Kogan EA. J Drugs Dermatol. 2017;16(1):68-74.
8 Schachter D, et al. J Drugs Dermatol. 2016 Aug 1; 15(8): 1005-10.
9 Sundaram H, et al. Dermatol Surg. 2010;36 (suppl 3):1859-1865.
10 Schachter Science Brief: Pain Control using the Injectable Dermal Filler Radiesse (+) for the correction of Nasolabial folds. Daniel Schachter, Vince Bertucci, Nowell Solish. POSTER PRESENTATION at 13th Anti-Aging Medicine World Congress (2015), Monaco, Monte Carlo.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201020005619/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kinaxis Named a Leader in Five 2026 IDC MarketScapes for Worldwide Supply Chain Planning13.11.2026 13:00:00 CET | Press release
Maestro delivers concurrent planning on a single platform across discrete, process, consumer packaged goods and life sciences Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain planning and orchestration, today announced it has been named a Leader in five 2026 IDC MarketScape vendor assessments for worldwide supply chain planning. The recognition spans the overall market and four industries - discrete industries, process industries, consumer packaged goods and life sciences industries - all served by a single platform, Kinaxis Maestro®, the company's AI-powered supply chain orchestration platform. "Supply chain leaders don't need a better forecast once a month. They need to know what changed this morning, what it means across the business, and what to do about it," said Andrew Bell, Chief Product Officer of Kinaxis. "I believe being named a Leader across five IDC MarketScape vendor assessments, in industries that plan in very different ways, shows that a single concurr
SBC Medical Announces Capital and Business Alliance with NeuroBrain Dynamics to Advance Clinic Profitability Through Medical AI13.11.2026 12:30:00 CET | Press release
Companies to co-develop six medical AI solutions targeting revenue expansion and cost reduction; SBC Medical secures priority sales rights in Japan and South Korea and targets B2B expansion across Asia SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“The Company” or “SBC Medical”), a Medical Services Organization (MSO) providing management support across a wide range of healthcare fields, today announced a strategic capital and business alliance agreement with NeuroBrain Dynamics Inc. (“NBD”), a Taipei-based company dedicated to enterprise generative AI solutions. As part of the agreement executed on November 13, 2026, SBC Medical has made a minority equity investment in NBD. Through this alliance, SBC Medical plans to introduce two complementary suites of generative AI solutions across its network of 287 clinics in Japan and overseas*: “revenue-growth AI,” to elevate average revenue per visit and customer retention through personalized customer guidance, and “cost-reduction AI,
SBC Medical Group Holdings Reports Third Quarter 2026 Financial Results13.11.2026 12:30:00 CET | Press release
Revenue Up 35%, Net Income Attributable to SBC Medical Up 22%, and Adjusted EBITDA1 Up 66% Year-over-Year; Net Income Margin of 27% and Adjusted EBITDA Margin of 47% — Previously Announced Service Fee Revisions and New Clinic Openings Contribute to Revenue Growth and Operating Margin Improvement SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a Medical Services Organization (MSO) providing management support across a wide range of healthcare fields to medical institutions in Japan and abroad, today announced its consolidated financial results for the third quarter of fiscal year 2026 (the three months ended September 30, 2026) and the three cumulative quarters of fiscal year 2026 (the nine months ended September 30, 2026). Third Quarter 2026 Financial Highlights Total revenues were $59 million, up 35% year-over-year. Income from operations was $26 million, up 66% year-over-year, with an operating margin of 45%. Net income attributable to SBC Medi
Interactive Brokers Offers Eligible Clients Access to the Anthropic, PBC Initial Public Offering13.11.2026 11:00:00 CET | Press release
ADVERTISEMENT This advertisement constitutes an advertisement within the meaning of the Prospectus Regulation and marketing communication within the meaning of MiFID II and is prepared by and in the sole responsibility of Interactive Brokers Ireland Limited, North Dock One, 91/92 North Wall Quay, Dublin 1, D01 H7V7, Ireland, a firm authorized and regulated by the Central Bank of Ireland. Eligible clients of Interactive Brokers Ireland Limited can participate in the offering. Interactive Brokers Ireland Limited, part of Interactive Brokers Group (Nasdaq: IBKR), an automated global broker, today announced that eligible clients can participate in the initial public offering (the “Offering”) of Anthropic, PBC (the “Company”). Through the IBKR platform, eligible clients resident and located in Denmark, Finland, France, Germany, Ireland, the Netherlands, Norway, Spain, and Sweden can review the Offering and submit an application during the offer period, which is open for all eligible clients
Yamaha to Acquire Disguise, Expanding Its Capabilities in Integrated Audio, Video, Lighting and Media13.11.2026 08:00:00 CET | Press release
Acquisition combines Yamaha’s audio expertise with Disguise’s software and media server technologies Yamaha Corporation today announced an agreement to acquire Disguise Technologies Limited (“Disguise”), a London-based provider of software and media server technologies for live and immersive experiences. Yamaha will acquire the company by purchasing all shares in its parent, Butterfly Topco Limited. The acquisition will expand Yamaha’s capabilities beyond audio into integrated audio, video, lighting and media solutions, in line with its strategy to expand beyond hardware into software and services. By combining Yamaha’s audio expertise and global reach with Disguise’s software, technologies and worldwide partner network, the companies will be better positioned to deliver immersive experiences across live entertainment, sports and other venues. Disguise’s technology powers live and immersive experiences worldwide, including tours by Beyoncé and Taylor Swift and venues such as New York’s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom